Advertisement
Monday, Nov 29, 2021
Outlook.com
Outlook.com

Tarsons Products Shares List With Nearly 6% Gain. Should You Buy?

The stock listed at Rs 700, a gain of 5.74 per cent against the issue price on BSE. It further jumped 22.05 per cent to Rs 808. On NSE, it listed with a premium of 3.02 per cent at Rs 682.

Tarsons Products Shares List With Nearly 6% Gain. Should You Buy?
Tarsons Products Shares List With Nearly 6% Gain. Should You Buy?
outlookindia.com
2021-11-26T11:38:46+05:30

Shares of life sciences company Tarsons Products on Friday listed with a premium of nearly 6 per cent against its issue price of Rs 662.

The stock listed at Rs 700, a gain of 5.74 per cent against the issue price on BSE. It further jumped 22.05 per cent to Rs 808. On NSE, it listed with a premium of 3.02 per cent at Rs 682.

The initial public offer of Tarsons Products Limited received 77.49 times subscription earlier this month.

The Rs 1,023.84-crore IPO had a price range of Rs 635-662 per share.

Here is what analysts had said about Tarsons Products listing:

Ravi Singhal, Vice Chairman at GCL Securities

Demand for Tarsons products are expected to scale northward and hence I would advise long-term investors to hold the counter for 3 months target of Rs 999 maintaining strict stop loss at Rs 735 levels. However, for those who missed getting Tarsons Products shares during the allotment process, my advice for them is to wait till the market stablises as falling markets may bring down Tarsons shares at a discounted price.

Aayush Agrawal, Sr. Research Analyst - Merchant Banking, Swastika Investmart

Tarsons Products has strong financials where margins are very impressive and it also has well-experienced management. The company has strong cash flows and it is likely to become debt-free post IPO. However, the valuations look expensive therefore aggressive investors with a long-term view can hold this stock while those who were playing for listing gains should book profit.

Santosh Meena, Head of Research at Swastika Investmart Ltd

Tarsons Products Limited is backed by a strong management team with great brand awareness and high-quality goods. It is one of the leading life sciences suppliers in India. The company aims to be debt fee post the IPO and is planning for CAPEX, which will further increase the revenues.

We may see profit booking in the stock eyeing the global cues on the concerns of a new variant of Covid-19. However, it is expected that we may see demand for the products of Tarsons in coming quarters. So, long-term investors can hold the stock whereas risk-taking investors can buy the stock maintaining stop loss at Rs 590 levels.

Abhay Doshi, Founder at UnlistedArena

The IPO of Tarsons Products Limited got a decent response from the participants despite priced on the higher side. Strong growth prospects along with decent margins made the issue attractive.

In my view, the issue should reward investors on listing and it may list somewhere around Rs 800 to Rs 850 translating to around 20 per cent gains, which are reasonable.

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

Read More from Outlook

Heavy Fines, Media Gag: Maharashtra Learns From Past As It Gears To Tackle Omicron

Heavy Fines, Media Gag: Maharashtra Learns From Past As It Gears To Tackle Omicron

Maharashtra CM Uddhav Thackeray has instructed all the ministers in charge of the districts to tighten coordination with the local administration to ensure proper prevention of another Covid-19 outbreak.

Omicron Shows Why Countries Need To Start Sharing Their Vaccines

Omicron Shows Why Countries Need To Start Sharing Their Vaccines

'Despite the repeated warnings of health leaders, our failure to put vaccines into the arms of people in the developing world is now coming back to haunt us', wrote former British PM Gordon Brown.

Iyer Plays Down Record, Says 'Important Thing Is To Win Match'

Iyer Plays Down Record, Says 'Important Thing Is To Win Match'

Shreyas Iyer hit 105 and 65 against New Zealand to become the first Indian batter to score a century and half-century in his debut Test match.

Covid-19: Experts' Take On Omicron And Possibility Of Third Wave In India

Covid-19: Experts' Take On Omicron And Possibility Of Third Wave In India

Though the health experts and scientists in India have advised caution yet they feel that the current immune profile of the majority of the population in India makes them less vulnerable to Omicron as compared to any other country in the world.

Advertisement